Candela's Vbeam laser approved in Japan
This article was originally published in Clinica
Executive Summary
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Candela Corporation's Vbeam laser system for the treatment of vascular conditions. The company, a subsidiary of Syneron Medical, claims that the technology is the first and only long pulsed dye laser system to be approved in Japan. The device can be used to treat vascular lesions such as rosacea, facial and leg veins, and haemangioma, a benign tumour caused by an abnormal build up of blood vessels. It can also be used for aesthetic procedures such as removal of sun spots, wrinkles, stretch marks and warts. The laser delivers energy to patients' underlying blood vessels but does not affect superficial skin layers, the Wayland, Massachusetts firm says.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.